Signal transduction as a therapeutic target

Current Topics in Microbiology and Immunology

Volumn 213 III, Issue , 1996, Pages 167-188

  Alessandro, R ^a   Spoonster, J ^a   Wersto, R P ^a   Kohn, E C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN TYROSINE KINASE;

CLINICAL TRIAL; HUMAN; METASTASIS; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029992444     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80071-9_11     Document Type: Review

References (122)

1. Akinaga S, Gomik K et al (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C in murine and human tumor models. Cancer Res 51: 4888-4892
2. Akiyama T, Ishida J et al (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 5592-5595
3. Alberts AW, Chen J et al (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and α cholesterol lowering agent Proc Natl Acad Sci USA 77 3957-3961
4. Albino AP, Schwartz GK et al (1995) Possible roles of bFGF and PKC in the evolution of metastases in malignant melanoma and gastric adenocarcinoma Bull Inst Pasteur 92. 276-284
5. Andreeson R (1988) Ether lipids in the therapy of cancer. Prog Biochem Pharmacol 22 118-131
6. Arteaga CL, Johnson MD et al (1991) Elevated content of the tyrosine kinase substrates phospholipase C-γ1 in primary human breast carcinomas Proc Natl Acad Sci USA 88: 10435-10439
7. Bailar JC, Smith E (1986) Progress against cancer? New Engl J Med 314: 1226-1232
8. Barbacid M (1987) Ras genes Annu Rev Biochem 56. 779-827
9. Bargmann CI, Hung MC et al (1986) The neu oncogene encodes an epidermal growth factor-related protein Nature 319: 226-230
10. Berdel WE (1991) Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer 64: 208-211
11. Berggren M, Gallegos A et al (1993) Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues Cancer Res 53 4297-4302
12. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235-248
13. Bos JL (1990) Ras gene mutations and human cancer. Elsevier, Amsterdam
14. Bottaro DP, Rubin JS et al (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product Science 152: 802-804
15. Boyle WJ, Smeal T et al (1991) Activation of protein kinase C decreases phosphorylation of c-jun at sites that negatively regulate its DNA-binding activity Cell 64 573-584
16. Buchdunger E, Trinks U et al (1994) 4,5-Dianilinophtalimide: a protein-tyrosine kinases inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 91. 2334-2338
17. Cantley LC, Auger KR et al (1991) Oncogenes and signal transduction. Cell 64: 281-302
18. Chen R, Sarnecki C et al (1992) Nuclear localization and regulation of erk- and rsk-encoded protein kinases Mol Cell Biol 12: 915-927
19. Clapham DE (1995) Calcium signaling. Cell 80: 259-268
20. Cole KA, Kohn EC (1994) Calcium-mediated signal transduction: biology, biochemistry, and therapy. Cancer Metastasis Rev 13: 33-41
21. Coughlin SR, Escobedo JA et al (1989) Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science 243: 1191-1194
22. Davis RJ (1993) The mitogen-activated protein kinase signal transduction pathway J Biol Chem 268: 14553-14556
23. Delli-Bovi P, Curatola AM et al (1987) An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is member of the FGF family Cell 50: 729-737
24. Deuel TF (1987) Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol 3: 443-492
25. Dougall WC, Qian X et al (1994) The neu-oncogene. 9: 2109-2123
26. Downward J, Yarden Y et al (1984) Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature 307: 521-527
27. Fearon EN, Vogelstein BA (1990) Genetic model for colorectal tumorgenesis Cell 53: 759-767
28. Felder CC, Ma AL et al (1991) The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 257. 967-971
29. 2+. Proc Natl Acad Sci USA 89: 509-513
30. Felder CC, MacArthur L et al (1993) Tumor-suppressor function of muscarinic acetylcholine receptors is associated with activation of receptor-operated calcium influx. Proc Natl Acad Sci USA 90(5): 1706-1710
31. Felder CC, Singer-Lahat D et al (1994) Voltage-independent calcium channels. Regulation by receptors and intracellular calcium stores. Biochem Pharmacol 48(11): 1997-2004
32. Fidler IJ, Hart IR, (1982) Biologic diversity in metastatic neoplasms - origins and implications Science 217: 998-1001
33. Fry MJ (1994) Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biopys Acta 1226: 237-268
34. Furcht L (1986) Critical factors controlling angiogenesis: cell products, cell matrix, and growth factor Lab Invest 5: 505-509
35. Furuya Y, Lundmo P et al (1994) The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54: 6167-6175
36. Galkina SI, Sud'Ina GF et al (1992) Cell-cell contacts alter intracellular pH. Exp Cell Res 200: 211-214
37. Ganz MB, Pachter JA et al (1990) Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP. J Biol Chem 265: 8989-8992
38. Gazit A, Osherow N et al. (1991) Tyrphostins II: heterocyclic and α-substituted benzylide-nemalononitrile tyrphostins as potent inhibitors of EGF receptors and ErbB2/Neu tyrosine kinases. J Med Chem 34: 1897-1907
39. Gibbs JB (1991) Ras C-terminal processing enzymes - new drug targets? Cell 65: 1-4
40. Gibbs JB, Oliff A et al (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77(2): 175-8
41. Goodnight J, Kazanietz MG et al (1992) The cDNA sequence, expression pattern and protein characteristics of mouse protein kinase C-zeta. Gene 122: 305-311
42. Gusovsky F, Lueders JE et al (1993) Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma: alternative mechanism for cholinergic receptor-induced phosphoinositide breakdown. J Biol Chem 268 7768-7772
43. Haag JD, Lindstrom MJ et al (1992) Limonene-induced regression of mammary carcinomas. Cancer Res 52: 4021-4026
44. Hancock JF, Magee AI et al (1989) All ras proteins are polyisoprenylated but only some are palmitoylated Cell 57: 1167-1177
45. Hennigan RF, Hawker KL et al (1994) Fos-transformation activates genes associated with invasion Oncogene 9: 3591-3600
46. Hilgard P, Kienner T et al (1993) Alkylphosphocolines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32: 90-95
47. Holmes K, Chaffins AS et al (1993) Quantitation of human plasma levels of the anticancer agent carboxyamido-triazole by high performance liquid chromatography. J Chrom Biomed Appl 613: 317-325
48. ++ entry, toward a proliferation or a simplification? Fed Am Soc Exp Biol J 6. 3085-3091
49. Isakov N, Gopas J et al (1991) Effect of protein kinase C activating tumor promoters on metastases formation by fibrosarcoma cells. Invasion Metastasis 11: 14-24
50. Iyer A, Kmieccik TE et al (1990) Structure, tissue-specific expression, and transforming activity of the mouse met-proto-oncogene Cell Growth Differ 1: 87-95
51. Kaplan DR, Whitman M et al (1987) Common elements in growth factor stimulation and oncogenic transformation. 85 kD phosphoprotein and phosphatidylinositol kinase activity Cell 50: 1021-1029
52. Khanavkar B, Ulbrich F et al (1989) Treatment of non-small cell lung cancer with the alkyl-lysophospholipid edelfosine Contrib Oncol 37: 224
53. Koch CA, Anderson D et al (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668-674
54. Kohl NE, Wilson FR et al (1994) Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice Proc Natl Acad Sci USA 91: 9141-9145
55. Kohn EC, Liotta LA (1990) L651582, a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82: 54-60
56. Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention Cancer Res 55. 1856-1862
57. Kohn EC, Sandeen MA et al (1992) In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates Cancer Res 52: 3208-3212
58. Kohn EC, Felder CC et al (1994a) Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI Cancer Res 54: 935-942
59. Kohn EC, Jacobs W et al (1994b) Calcium influx modulates expression of matrix metalloproteinases-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269: 21505-21511
60. Kohn EC, Alessandro R et al (1995) Angiogenesis role of calcium-mediated signal transduction. Proc Natl Acad Sci USA
61. Kohn EC, Reed E et al (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Research (in press)
62. Kovalenko M, Gazit A et al (1994) Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 54 6106-6114
63. Kypta RM, Goldberg Y et al (1990) Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 62. 481-492
64. Lagarde AE, Pouyssegur JM (1986) The Na+ H+ antiport in cancer. Biochim Biophys Acta 9: 1-14
65. Leevers SJ, Marshall CJ (1992) MAP kinase regulation - the oncogene connection. Trends Cell Biol 2: 283-285
66. Lehel S, Lasic Z et al (1994) Collagen type IV stimulates an increase in intracellular calcium in pancreatic acinar cells via activation of phospholipase C. Biochem J 299. 603-611
67. Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis Cancer Metastasis Rev 11: 31-44
68. Lev SJ, Blechman M et al (1994) Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog 5: 141-168
69. Levitzki A (1994) Signal-transduction therapy Eur J Biochem 226: 1-13
70. Liotta LA, Steeg PS et al (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327
71. Macara IG (1989) Oncogenes and signal transduction. Physiol Rev 69: 797-820
72. Margolis B (1992) Protein with SH2 domain: transducers in the tyrosine kinase signalling pathway. Cell Growth Differ 3: 73-80
73. Markovits J, Linassier C et al (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49. 5111-5117
74. Matrisian L (1992) The matrix-degrading metalloproteinases. Bioessay 14: 455-462
75. Matter WF, Brown RF et al (1992) The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophy Res Commun 186 624-631
76. Mazzanti M, DeFelice LJ et al (1990) Ion channels in the nuclear envelope Nature 343. 764-767
77. McCormick F (1993) How receptors turn Ras on Nature 363: 15-16
78. Millon R, Nicora F et al (1989) Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin Exp Metastasis 7: 405-415
79. Mischak H, Kolch W et al (1991) Expression of protein kinase C genes in hemepoietic cells is cell-type and B-cell differentiation stage specific. J Immunol 147: 3981-3987
80. Naldini L, Weidner KM et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10: 2867-2878
81. Neer EJ (1995) Heterotrimeric G proteins, organizers of transmembrane signals Cell 80. 249-257
82. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 606-614
83. Nixon JS, Bishop J et al (1992) The design and biological properties of potent and selective inhibitors of protein kinase C. Biochem Soc Trans 20: 419-425
84. Noh D, Lee YH et al (1993) Elevated content of phospholipase C-γ1 in colorectal cancer tissues. Cancer 73: 36-41
85. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23-28
86. O'Brian CA, Housey GM et al (1988) Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 48: 3626-3629
87. Osherow N, Levitzki A (1994) Epidermal growth factor dependent activation of src family kinases. Eur J Biochem 225: 1047-1053
88. Paterson MC, Dietrich KD et al (1991) Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51: 556-567
89. Peles E, Lamprecht R et al (1992) Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation J Biol Chem 267: 12266-12274
90. Powis G (1994) Recent advances in the development of anticancer drugs that against signaling pathways. Tumori 80: 69-87
91. Powis G, Bonjouklian R et al (1994) Wortmanin, a potent and selective inhibitor of phosphatidylinositol-3-kinase Cancer Res 54: 2419-2423
92. Powis G, Seewald MJ et al (1992) Selective inhibition of phosphatidylinositol phospholipase C by citotoxic ether lipid analogues Cancer Res 52: 2835-2840
93. 2+ stores releases a novel small messenger that stimulates Ca2+ influx. Nature 364: 809-814
94. Reeve J (1991) Mitogenesis and the search for new targets for anticancer drug design. Tumour Biol 12(1): 1
95. Rilemma JA (1989) Possible roles of phospholipase C in the regulation of cell division in normal and neoplastic cells Med Hypothesis 29: 1-4
96. Rong S, Segal S et al (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 91: 4731-4735
97. Sardet C, Counillo L et al (1990) Growth factors induce phosphorylation of the Na+/H+ antiporter, a glycoprotein of 110 kD. Science 247: 723-726
98. Sato H, Takino T et al (1994) A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65
99. Savarese DMF, Russell JT et al (1992) Type IV collagen stimulates an increase in intracellular calcium: potential role in tumor cell motility. J Biol Chem 267: 21928-21935
100. Schafer WR, Rine J (1992) Protein prenylation: genes, enzymes, targets and functions. Annu Rev Genetics 30: 209-237
101. Schallier DK, Brunyneel EA et al (1991) Anti-invasive activity of hexadecylophosphocholine in vitro. Anticancer Res 11 1285-1292
102. Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9: 383-391
103. Schu PV, Takegawa K et al (1993) Phophatidyl-inositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting Science 260: 88-91
104. Schwartz GK, Jiang J et al (1993) Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85: 402-407
105. Schwartz GK, Redwood SM et al (1990) Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst 82: 1753-1756
106. Sebti SM, Tkalcevic GT et al (1991) Lovostatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 3. 141-146
107. 2+ signaling by antitumor ether lipid analogues. Cancer Res 50: 4458-4463
108. Sherr CJ, Rettenmier CW et al (1985) The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41 665-676
109. 2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA 90: 4986-4990
110. Simon ML, Strathmann MP et al (1991) Diversity of G proteins in signal transduction. Science 252: 802-808
111. Smith MR, Liu YL et al (1990) Inhibition of serum- and Ras-stimulated DNA synthesis by antibodies to phospholipase C. Science 247: 1074-1077
112. Soriano PC, Montgomery R et al (1991) Targeted disruption of the c-src protoncogene leads to osteoporosis in mice. Cell 64: 693-702
113. Taylor JM, Simpson RV (1992) Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 52(9): 2413-2418
114. Thibault A et al (1995) Lovastatin in phase I and II clinical trials (submitted)
115. Thibault A, Samid D, Tompkins AC, Figg WD, Liang B, Patronas N, Hohl RJ, Cooper MR, Venzon DJ, Reed E, Myers CE (1996) A phase I study of lavastatin, in inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res (in press)
116. Uberall F, Oberhuber H et al (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51: 807-812
117. Umezawa H, Imoto M et al (1986) Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3 J Antibiot (Tokyo) 39: 170-173
118. Velu TJ, Beguinot L et al (1987) Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238: 1408-1410
119. Waterfield MD, Scrace GT et al (1983) Platelet-derived growth factor is structurally related to the putative transforming protei p28sis of simian sarcoma virus. Nature 304. 35-39
120. Williams NG, Roberts TM (1994) Signal transduction pathways involving the raf proto-oncogene. Cancer Metastasis Rev 13: 105-116
121. Yaish P, Gazit A et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinases inhibitors Science 242. 933-935
122. Zong CS, Wang L (1994) Modulatory effect of the transmembrane domain of the protein kinase encoded by oncogene ros: biological function and substrate interaction. Proc Natl Acad Sci USA 91: 10982-10986